How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
Identifieur interne : 000447 ( PubMed/Corpus ); précédent : 000446; suivant : 000448How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
Auteurs : P. Conti ; C E Gallenga ; G. Tetè ; Al Caraffa ; G. Ronconi ; A. Younes ; E. Toniato ; R. Ross ; S K KritasSource :
- Journal of biological regulators and homeostatic agents [ 0393-974X ] ; 2020.
Abstract
SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19.
DOI: 10.23812/Editorial-Conti-2
PubMed: 32228825
Links to Exploration step
pubmed:32228825Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.</title><author><name sortKey="Conti, P" sort="Conti, P" uniqKey="Conti P" first="P" last="Conti">P. Conti</name><affiliation><nlm:affiliation>Postgraduate Medical School, University of Chieti, Chieti, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gallenga, C E" sort="Gallenga, C E" uniqKey="Gallenga C" first="C E" last="Gallenga">C E Gallenga</name><affiliation><nlm:affiliation>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tete, G" sort="Tete, G" uniqKey="Tete G" first="G" last="Tetè">G. Tetè</name><affiliation><nlm:affiliation>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Caraffa, Al" sort="Caraffa, Al" uniqKey="Caraffa A" first="Al" last="Caraffa">Al Caraffa</name><affiliation><nlm:affiliation>School of Pharmacy, University of Camerino, Camerino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ronconi, G" sort="Ronconi, G" uniqKey="Ronconi G" first="G" last="Ronconi">G. Ronconi</name><affiliation><nlm:affiliation>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Younes, A" sort="Younes, A" uniqKey="Younes A" first="A" last="Younes">A. Younes</name><affiliation><nlm:affiliation>Medical Center "Mai più Dolore", Pescara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Toniato, E" sort="Toniato, E" uniqKey="Toniato E" first="E" last="Toniato">E. Toniato</name><affiliation><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ross, R" sort="Ross, R" uniqKey="Ross R" first="R" last="Ross">R. Ross</name><affiliation><nlm:affiliation>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kritas, S K" sort="Kritas, S K" uniqKey="Kritas S" first="S K" last="Kritas">S K Kritas</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32228825</idno><idno type="pmid">32228825</idno><idno type="doi">10.23812/Editorial-Conti-2</idno><idno type="wicri:Area/PubMed/Corpus">000447</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000447</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.</title><author><name sortKey="Conti, P" sort="Conti, P" uniqKey="Conti P" first="P" last="Conti">P. Conti</name><affiliation><nlm:affiliation>Postgraduate Medical School, University of Chieti, Chieti, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Gallenga, C E" sort="Gallenga, C E" uniqKey="Gallenga C" first="C E" last="Gallenga">C E Gallenga</name><affiliation><nlm:affiliation>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Tete, G" sort="Tete, G" uniqKey="Tete G" first="G" last="Tetè">G. Tetè</name><affiliation><nlm:affiliation>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Caraffa, Al" sort="Caraffa, Al" uniqKey="Caraffa A" first="Al" last="Caraffa">Al Caraffa</name><affiliation><nlm:affiliation>School of Pharmacy, University of Camerino, Camerino, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ronconi, G" sort="Ronconi, G" uniqKey="Ronconi G" first="G" last="Ronconi">G. Ronconi</name><affiliation><nlm:affiliation>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Younes, A" sort="Younes, A" uniqKey="Younes A" first="A" last="Younes">A. Younes</name><affiliation><nlm:affiliation>Medical Center "Mai più Dolore", Pescara, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Toniato, E" sort="Toniato, E" uniqKey="Toniato E" first="E" last="Toniato">E. Toniato</name><affiliation><nlm:affiliation>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Ross, R" sort="Ross, R" uniqKey="Ross R" first="R" last="Ross">R. Ross</name><affiliation><nlm:affiliation>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Kritas, S K" sort="Kritas, S K" uniqKey="Kritas S" first="S K" last="Kritas">S K Kritas</name><affiliation><nlm:affiliation>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of biological regulators and homeostatic agents</title><idno type="ISSN">0393-974X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32228825</PMID><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0393-974X</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>03</Month><Day>31</Day></PubDate></JournalIssue><Title>Journal of biological regulators and homeostatic agents</Title><ISOAbbreviation>J. Biol. Regul. Homeost. Agents</ISOAbbreviation></Journal><ArticleTitle>How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.23812/Editorial-Conti-2</ELocationID><Abstract><AbstractText>SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19.</AbstractText><CopyrightInformation>Copyright 2020 Biolife Sas. www.biolifesas.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Postgraduate Medical School, University of Chieti, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallenga</LastName><ForeName>C E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences and Specialist Surgery, Section of Ophthalmology, University of Ferrara, Ferrara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tetè</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Specialization School in Oral Surgery, Vita-Salute San Raffaele University, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caraffa</LastName><ForeName>Al</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of Camerino, Camerino, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronconi</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinica dei Pazienti del Territorio, Fondazione Policlinico Gemelli, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Younes</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Medical Center "Mai più Dolore", Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toniato</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Chieti, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kritas</LastName><ForeName>S K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>J Biol Regul Homeost Agents</MedlineTA><NlmUniqueID>8809253</NlmUniqueID><ISSNLinking>0393-974X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID</Keyword><Keyword MajorTopicYN="Y">CoV-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">coronavirus</Keyword><Keyword MajorTopicYN="Y">fibrosis</Keyword><Keyword MajorTopicYN="Y">inflammation</Keyword><Keyword MajorTopicYN="Y">lung</Keyword><Keyword MajorTopicYN="Y">virus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32228825</ArticleId><ArticleId IdType="doi">10.23812/Editorial-Conti-2</ArticleId><ArticleId IdType="pii">27</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000447 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000447 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:32228825
|texte= How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:32228825" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |